The person behind the work.
A founder working across medicines and the next frontier
Varun Sharma is a Glasgow-born British-Indian entrepreneur and the founder of NEUVIOR and the VARUNÉ portfolio. At NEUVIOR, he serves as CEO and CTO and is product architect of PHARMORIS. His work centres on a practical question: how can complex evidence become a useful decision, with a clear human owner responsible for what happens next?
The education of family business
His early education in business came from his father’s corner shop. Writing in Startups Magazine, he recalls asking at seven why a chocolate bar sold for more than its purchase cost, and learning how margins support the costs of running a business. He connects those lessons in cash, customer behaviour and trust to his present interest in systems that turn ambition into reliable execution.
Building medicines intelligence
NEUVIOR gives that approach a focused setting. PHARMORIS is being developed as a staff-facing, human-governed medicines-operations system: a way to connect reviewable evidence, authorised decisions and accountable follow-through. Varun leads the product’s architecture alongside the company’s direction. The work remains in controlled, non-production development; its ambition is to make the route from evidence to action more explicit, rather than leave responsibility scattered across disconnected records.
A public argument about implementation
His published work follows the same thread. In pharmaphorum, he examines why medicines approval does not automatically become access. In TechRadar Pro, he asks how organisations can tell whether they retain control of an AI system. His September 2026 Express Pharma contribution considers the proofs behind India’s pharmaceutical capability. As a guest on AI Ethics Now, the University of Warwick IATL podcast, he discusses when an AI suggestion becomes a decision for which a person or institution must answer.
The wider VARUNÉ portfolio
Alongside NEUVIOR PHARMACEUTICALS LTD, the portfolio includes VARUNÉ BIOSYSTEMS LTD, VARUNÉ SPACE SYSTEMS LTD and VARUNÉ INTELLIGENCE LTD. Biosystems has five proposed research interests: biological timing and chronobiology; ageing and longevity; repair, regeneration and rejuvenation; medicines, therapeutics and formulations; and skin, hair, skincare and aesthetics. Space Systems is the current exploratory, precommercial space direction. Intelligence explores AI and robotics for complex real-world problems. NEUVIOR and PHARMORIS remain the present operating focus while those wider directions take shape.
From research questions to things worth building
VARUNÉ Labs extends the ambition into medicines, novel formulations, generics, skincare and personal care, fragrance and sensory research, and longer-range manufacturing plans. It is a predevelopment programme operated by NEUVIOR, with no confirmed facility or manufacturing capability. VARUNÉ Group is the shared portfolio brand, not a legal parent company. Across these distinct businesses and programmes, Varun’s connecting interest is how ideas become useful through human judgement, disciplined development and practical implementation.
Historical identity note. A limited number of earlier publisher and public records use Varun Cruz. The name is retained here only to connect those records to Varun Sharma. Use Varun Sharma for current biographies, titles and metadata.